Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: AIT test has no problem in the detection of anti-ribosomal P. | Available online http content 11 3 407 Letter AIT test has no problem in the detection of anti-ribosomal P La-He Jearn and Think-You Kim Department of Early Arthritis Laboratory Medicine The Hospital for Rheumatic Diseases Hanyang University Medical Center 133-792 Seoul Republic of Korea Corresponding author Think-You Kim tykim@ Published 15 June 2009 Arthritis Research Therapy 2009 11 407 doi ar2705 This article is online at http content 11 3 407 2009 BioMed Central Ltd See related research by Mahler et al. http content 10 6 R131 Mahler and colleagues posed a question on the reliability of the indirect immunofluorescence method using the HEp-2 cell line in their recent Arthritis Research and Therapy article 1 . Products from three different companies showed different staining patterns on the same anti-ribosomal P anti-Rib-P in the pictures they revealed. In addition to the anti-Rib-P that Mahler and colleagues mentioned limitations of the HEp-2 cell line in the detection of autoantibodies such as anti-Ro have long been pointed out. The HEp-2000 cell line which was developed to overcome such limitations did not show any superior performance in the detection of anti-Rib-P since it was a form of HEp-2 cell that was transfected with cDNA encoding human Ro60. A human macrophage cell line called the IT-1 cell line was first introduced at the American College of Rheumatology meeting held in Minneapolis in 1994 2 the same time as HEp-2000 was presented. IT-1 had been commercialized and passed inspection by the Korea Food and Drug Administration in South Korea. Currently IT-1 is being used under the name of the autoimmune target AIT test and it participates in the quality control program run by the Korean Society of Laboratory Medicine 3 . In 1999 and 2007 reports of antinuclear antibody test using the IT-1 cell line on 208 and 588 systemic lupus erythematosus SLE patients .
